Population Pharmacokinetics and Exposure–Response Relationships of Etrolizumab in Patients with Moderately‐to‐Severely Active Crohn's Disease
The Journal of Clinical Pharmacology · 2025
DOI: 10.1002/jcph.70043 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift The Journal of Clinical Pharmacology, 2025. Verfasst von Anita Moein und 4 weiteren Autor:innen. Beteiligte Einrichtung: Genentech, Inc., South San Francisco, CA, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Crohn Disease, Anti-Inflammatory Agents, Non-Steroidal. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
This study aimed to characterize the pharmacokinetics (PK) of etrolizumab, an IgG1‐humanized monoclonal anti‐β7 integrin antibody, and assess its exposure–response (ER) relationship for key clinical outcomes in patients with moderately‐to‐severely active Crohn's disease. ER analyses were based on data from Phase 3 BERGAMOT trial, which evaluated etrolizumab at 105 or 210 mg during induction phase and 105 mg during maintenance phase. Population pharmacokinetic analysis was performed to characterize etrolizumab PK and identify influential covariates. ER analyses were conducted at end of induction and maintenance for clinical remission, endoscopic improvement, and endoscopic remission. ER modeling was performed using logistic regression, and full covariate model was used to examine the impact of baseline covariates on clinical outcomes. Pharmacokinetics of etrolizumab was best characterized using a two‐compartment model with first‐order absorption, demonstrating a time‐dependent decrease in clearance. Typical maximum reduction of clearance was 22.0% (95% CI: 20.5%‐23.5%) with onset half‐life of 3.45 (95% CI: 2.84‐4.04) weeks. Baseline body weight, albumin, and C‐reactive protein were the most impactful covariates for etrolizumab exposure. Based on population PK results, trough concentration at Week 4 of induction was selected as exposure metric. Etrolizumab exposure–response slope was significant ( P < .05) for clinical remission, endoscopic improvement, and endoscopic remission final models in maintenance phase, but none of final ER models of induction phase. For all induction ER endpoints, tumor necrosis factor (TNF)‐naive patients had significantly higher probability of a favorable outcome at end of induction compared to TNF‐experienced patients. In summary, exposure–response was more evident at end of maintenance than at end of induction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Genentech, Inc., South San Francisco, CA, USA.
- Pharmetheus AB, Uppsala, Sweden.
ORCID-Profile: Anita Moein, Moustafa M A Ibrahim, Nastya Kassir
Zitieren
APA
Moein, A., Ribbing, J., Ibrahim, M. M. A., Zhang, W., & Kassir, N. (2025). Population Pharmacokinetics and Exposure–Response Relationships of Etrolizumab in Patients with Moderately‐to‐Severely Active Crohn's Disease. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.70043
Vancouver
Moein A, Ribbing J, Ibrahim MMA, Zhang W, Kassir N. Population Pharmacokinetics and Exposure–Response Relationships of Etrolizumab in Patients with Moderately‐to‐Severely Active Crohn's Disease. The Journal of Clinical Pharmacology. 2025. doi:10.1002/jcph.70043
BibTeX
@article{Moein2025,
author = {Moein, Anita and Ribbing, Jakob and Ibrahim, Moustafa M A and Zhang, Wenhui and Kassir, Nastya},
title = {Population Pharmacokinetics and Exposure–Response Relationships of Etrolizumab in Patients with Moderately‐to‐Severely Active Crohn's Disease},
journal = {The Journal of Clinical Pharmacology},
year = {2025},
doi = {10.1002/jcph.70043}
}
EUVIMED